Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 98
Filter
3.
Med Mal Infect ; 49(5): 335-346, 2019 Aug.
Article in English | MEDLINE | ID: mdl-31155367

ABSTRACT

The serodiagnosis of Lyme borreliosis is based on a two-tier strategy: a screening test using an immunoenzymatic technique (ELISA), followed if positive by a confirmatory test with a western blot technique for its better specificity. Lyme serology has poor sensitivity (30-40%) for erythema migrans and should not be performed. The seroconversion occurs after approximately 6 weeks, with IgG detection (sensitivity and specificity both>90%). Serological follow-up is not recommended as therapeutic success is defined by clinical criteria only. For neuroborreliosis, it is recommended to simultaneously perform ELISA tests in samples of blood and cerebrospinal fluid to test for intrathecal synthesis of Lyme antibodies. Given the continuum between early localized and disseminated borreliosis, and the efficacy of doxycycline for the treatment of neuroborreliosis, doxycycline is preferred as the first-line regimen of erythema migrans (duration, 14 days; alternative: amoxicillin) and neuroborreliosis (duration, 14 days if early, 21 days if late; alternative: ceftriaxone). Treatment of articular manifestations of Lyme borreliosis is based on doxycycline, ceftriaxone, or amoxicillin for 28 days. Patients with persistent symptoms after appropriate treatment of Lyme borreliosis should not be prescribed repeated or prolonged antibacterial treatment. Some patients present with persistent and pleomorphic symptoms after documented or suspected Lyme borreliosis. Another condition is eventually diagnosed in 80% of them.


Subject(s)
Clinical Laboratory Techniques , Lyme Disease , Tick-Borne Diseases , Animals , Clinical Laboratory Techniques/methods , Clinical Laboratory Techniques/standards , Diagnosis, Differential , Disease Progression , France , Humans , Lyme Disease/complications , Lyme Disease/diagnosis , Lyme Disease/pathology , Lyme Disease/therapy , Practice Guidelines as Topic , Societies, Scientific/organization & administration , Societies, Scientific/standards , Tick-Borne Diseases/complications , Tick-Borne Diseases/diagnosis , Tick-Borne Diseases/pathology , Tick-Borne Diseases/therapy
4.
Med Mal Infect ; 49(5): 318-334, 2019 Aug.
Article in English | MEDLINE | ID: mdl-31097370

ABSTRACT

Lyme borreliosis is transmitted en France by the tick Ixodes ricinus, endemic in metropolitan France. In the absence of vaccine licensed for use in humans, primary prevention mostly relies on mechanical protection (clothes covering most parts of the body) that may be completed by chemical protection (repulsives). Secondary prevention relies on early detection of ticks after exposure, and mechanical extraction. There is currently no situation in France when prophylactic antibiotics would be recommended. The incidence of Lyme borreliosis in France, estimated through a network of general practitioners (réseau Sentinelles), and nationwide coding system for hospital stays, has not significantly changed between 2009 and 2017, with a mean incidence estimated at 53 cases/100,000 inhabitants/year, leading to 1.3 hospital admission/100,000 inhabitants/year. Other tick-borne diseases are much more seldom in France: tick-borne encephalitis (around 20 cases/year), spotted-fever rickettsiosis (primarily mediterranean spotted fever, around 10 cases/year), tularemia (50-100 cases/year, of which 20% are transmitted by ticks), human granulocytic anaplasmosis (<10 cases/year), and babesiosis (<5 cases/year). The main circumstances of diagnosis for Lyme borreliosis are cutaneous manifestations (primarily erythema migrans, much more rarely borrelial lymphocytoma and atrophic chronic acrodermatitis), neurological (<15% of cases, mostly meningoradiculitis and cranial nerve palsy, especially facial nerve) and rheumatologic (mostly knee monoarthritis, with recurrences). Cardiac and ophtalmologic manifestations are very rarely encountered.


Subject(s)
Lyme Disease , Tick-Borne Diseases , Animals , Babesiosis/diagnosis , Babesiosis/epidemiology , Babesiosis/therapy , Encephalitis, Tick-Borne/diagnosis , Encephalitis, Tick-Borne/epidemiology , Encephalitis, Tick-Borne/therapy , France/epidemiology , Humans , Ixodes/physiology , Lyme Disease/diagnosis , Lyme Disease/epidemiology , Lyme Disease/prevention & control , Practice Guidelines as Topic , Skin Diseases, Bacterial/diagnosis , Skin Diseases, Bacterial/epidemiology , Skin Diseases, Bacterial/therapy , Societies, Scientific/organization & administration , Societies, Scientific/standards , Tick-Borne Diseases/diagnosis , Tick-Borne Diseases/epidemiology , Tick-Borne Diseases/prevention & control
5.
Med Mal Infect ; 49(2): 112-120, 2019 Mar.
Article in English | MEDLINE | ID: mdl-30190164

ABSTRACT

OBJECTIVE: The teaching hospital of Nancy, France, implemented a specific multidisciplinary care pathway (French acronym AMDPL) to improve the management of patients presenting with Lyme borreliosis (LB) suspicion. We aimed to assess the first year of activity of this care pathway. PATIENTS AND METHODS: We included all patients managed in the AMDPL pathway from November 1, 2016 to October 31, 2017. The first step was a dedicated Lyme disease consultation with an infectious disease specialist. Following this consultation, the LB diagnosis was either confirmed and adequate treatment was prescribed, or a differential diagnosis was established and patients received adequate management, or further investigations were required and patients were offered multidisciplinary management as part of a day hospitalization. RESULTS: A total of 468 patients were included. LB diagnosis was confirmed in 15% of patients (69/468), 49% of patients received a differential diagnosis, and 26% (122/468) of patients had the LB diagnosis ruled out without receiving any other diagnosis. CONCLUSIONS: This is to our knowledge the first multidisciplinary center implemented in France for the management of patients presenting with LB suspicion related to polymorphous signs and symptoms. Several diagnoses could be confirmed or corrected, although some symptoms and complaints could not be explained. This cohort could improve our knowledge of LB and its differential diagnoses.


Subject(s)
Lyme Disease , Disease Management , France , Hospitals, Teaching , Humans , Lyme Disease/diagnosis , Lyme Disease/therapy
6.
Med Mal Infect ; 48(2): 95-102, 2018 Mar.
Article in English | MEDLINE | ID: mdl-29169817

ABSTRACT

CONTEXT: In 2012, the French Infectious Diseases Society (French acronym SPILF) initiated the "Coordination of epidemic and biological risk" (SPILF-COREB - Emergences [SCE]) group to support the readiness and response of healthcare workers (HCWs) to new alerts. OBJECTIVE: To present the SCE group, its functioning, and the main support it provided for frontline HCWs. METHODS: A multidisciplinary group of heads of infectious disease departments from reference hospitals was created to build a network of clinical expertise for care, training, and research in the field of epidemic and biological risk (EBR). The network developed a set of standardized operational procedures (SOPs) to guide interventions to manage EBR-suspect patients. RESULTS: A working group created the SOP aimed at frontline HCWs taking care of patients. Priority was given to the development of a generic procedure, which was then adapted according to the current alert. Five key steps were identified and hierarchized: detecting, protecting, caring for, alerting, and referring the EBR patient. The interaction between clinicians and those responsible for the protection of the community was crucial. The SOPs validated by the SPILF and its affiliates were disseminated to a wide range of key stakeholders through various media including workshops and the SPILF's website. CONCLUSION: SPILF can easily adapt and timely mobilize the EBR expertise in case of an alert. The present work suggests that sharing and discussing this experience, initiated at the European level, can generate a new collective expertise and needs to be further developed and strengthened.


Subject(s)
Coronavirus Infections/epidemiology , Coronavirus Infections/prevention & control , Epidemics/prevention & control , Hemorrhagic Fever, Ebola/epidemiology , Hemorrhagic Fever, Ebola/prevention & control , Middle East Respiratory Syndrome Coronavirus , France/epidemiology , Humans , Risk , Risk Factors , Societies, Medical
8.
Eur J Clin Microbiol Infect Dis ; 36(7): 1083-1090, 2017 Jul.
Article in English | MEDLINE | ID: mdl-28070748

ABSTRACT

In 2011, the French Agency for Safety of Health Products issued guidelines underlining the principles of proper aminoglycosides' use. The aim of the survey was to evaluate adherence to these guidelines two years after their issue. Characteristics of patients receiving aminoglycosides were recorded by voluntary facilities during a 3-month survey in 2013-2014. The modalities of aminoglycosides treatment were analysed by comparison with the French guidelines. A total of 3,323 patients were included by 176 facilities. Patients were mainly hospitalized in medical wards (33.0%), and treated for urinary-tract infections (24.7%). Compliance regarding the clinical indication and the daily aminoglycosides dose was observed in 65.2% and 62.9% of the cases, respectively. A 30-min once-daily IV administration was recorded in 62.5% of the cases. Aminoglycosides treatment duration was appropriate (≤5 days) for 93.6% of the patients. When considering the four criteria together, 23.2% of the patients had a treatment regimen aligned with the guidelines. Requests for measurements of peak and trough AG serum concentrations matched the guidelines in 24.9% and 67.4% of the cases, respectively. Two years after guidelines issue, aminoglycosides use remains unsatisfactory in French health-care facilities. Efforts should be made for guidelines promotion, especially regarding the issue of underdosing.


Subject(s)
Aminoglycosides/therapeutic use , Anti-Bacterial Agents/therapeutic use , Bacterial Infections/drug therapy , Guideline Adherence , Aged , Female , France , Hospitals , Humans , Male , Middle Aged
11.
Med Mal Infect ; 46(6): 276-84, 2016 Sep.
Article in English | MEDLINE | ID: mdl-27056661

ABSTRACT

OBJECTIVE: We aimed to assess the acceptability of antibiotic stewardship measures by family physicians. MATERIAL AND METHODS: We conducted an online cross-sectional survey in 2015 with a sample of family physicians practicing in a specific French region. RESULTS: Overall, 283 of 1171 family physicians (24%) completed the questionnaire. Decision-support tools for antibiotic prescribing and educational measures were well accepted by family physicians: 71% strongly agreed with a free distribution of urine dipstick tests and 54% with incentives to participate in antibiotic training sessions. Almost all family physicians did not agree with restrictive measures: 68% were for instance opposed to having to justify the prescription's compliance with guidelines on the prescription itself. Physicians also did not agree with restrictive measures when they only applied to physicians prescribing many antibiotics. CONCLUSION: Participants were probably the most motivated and aware of the topic physicians, but they were particularly hostile to the introduction of restrictive measures related to antibiotic prescribing. Our survey was conducted with a large sample of family physicians and could help orientate our country's antibiotic stewardship policy. However, family physicians are likely to oppose any measure aiming at restricting their freedom of prescription.


Subject(s)
Antimicrobial Stewardship , Attitude of Health Personnel , Physicians, Family/psychology , Primary Health Care/standards , Adult , Aged , Anti-Bacterial Agents/therapeutic use , Cross-Sectional Studies , Decision Support Techniques , Drug Prescriptions/standards , Female , France , Humans , Inappropriate Prescribing/prevention & control , Male , Middle Aged , Patient Education as Topic/methods , Professional Autonomy , Professional Practice , Reagent Kits, Diagnostic , Surveys and Questionnaires , Urinary Tract Infections/diagnosis , Urinary Tract Infections/drug therapy , Urinary Tract Infections/microbiology , Urine/microbiology
12.
Med Mal Infect ; 46(3): 140-5, 2016 May.
Article in English | MEDLINE | ID: mdl-26995289

ABSTRACT

OBJECTIVE: Abdominal tuberculosis is a rare disease. The clinical and radiological manifestations are non-specific and the diagnosis is difficult. Our objective was to describe the characteristics and treatment of patients presenting with abdominal tuberculosis in a low-incidence country. PATIENTS AND METHODS: We reviewed the clinical, diagnostic, treatment, and outcome features of patients presenting with abdominal tuberculosis diagnosed by bacteriological and/or histological results and managed in five French university hospitals from January 2000 to December 2009. RESULTS: We included 21 patients. The mean diagnostic delay was 13 months. Twelve patients (57%) came from a low-incidence area and only two had a known immunosuppressed condition. Eighteen patients (86%) presented with abdominal symptoms. The main organs involved were the peritoneum (n=14, 66%), the mesenteric lymph nodes (n=13, 62%), and the bowel (n=7, 33%). Sixteen patients (76%) underwent surgery, including two in an emergency setting. Seventeen patients (81%) received six months or more of anti-tuberculosis treatment. Finally, 16 patients (76%) had a positive outcome. CONCLUSION: New diagnostic procedures, and especially molecular biology, may help diagnose unusual clinical presentations of tuberculosis. Invasive procedures are frequently necessary to obtain samples but also for the treatment of digestive involvement.


Subject(s)
Tuberculosis, Gastrointestinal/epidemiology , Tuberculosis, Lymph Node/epidemiology , Adult , Africa/ethnology , Aged , Aged, 80 and over , Antitubercular Agents/therapeutic use , Asia/ethnology , Delayed Diagnosis , Emigrants and Immigrants , Female , France/epidemiology , Humans , Interferon-gamma Release Tests , Male , Middle Aged , Peritonitis, Tuberculous/diagnosis , Peritonitis, Tuberculous/drug therapy , Peritonitis, Tuberculous/epidemiology , Retrospective Studies , Sensitivity and Specificity , Symptom Assessment , Treatment Outcome , Tuberculosis, Gastrointestinal/diagnosis , Tuberculosis, Gastrointestinal/drug therapy , Tuberculosis, Gastrointestinal/surgery , Tuberculosis, Hepatic/diagnosis , Tuberculosis, Hepatic/drug therapy , Tuberculosis, Hepatic/epidemiology , Tuberculosis, Lymph Node/diagnosis , Tuberculosis, Lymph Node/drug therapy , Young Adult
13.
Med Mal Infect ; 45(11-12): 475-80, 2015.
Article in English | MEDLINE | ID: mdl-26612602

ABSTRACT

OBJECTIVES: We aimed to assess antibiotic prescriptions to identify potential targets for improvement. METHODS: We conducted a point prevalence survey (November 2010) of antibiotic use in 314 voluntary hospitals recruited by the French Infectious Diseases Society (SPILF) and the National Observatory for Epidemiology of Bacterial Resistance to Antimicrobials (ONERBA). Data were entered online, immediately analyzed and exported. RESULTS: The prevalence of antibiotic use was 19.5% (9059/46,446patients). A higher prevalence was observed in the infectious disease (58.4%), hematology (58%), and intensive care (48.7%) units. The three most frequently used antibiotic classes were aminopenicillins (23.8%), fluoroquinolones (17.9%), and 3rd-generation cephalosporins (16.7%). A monotherapy was prescribed to 64% of patients. The reasons for the antibiotic prescription were written in the medical records of 74% of patients and 62% were consistent with the local guidelines. CONCLUSION: Our results are similar to that of other studies. Various local targets for improvement have been identified to help hospitals define a better antibiotic stewardship.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Drug Utilization/statistics & numerical data , Drug Utilization/standards , Cross-Sectional Studies , Female , France , Hospitals , Humans , Male , Middle Aged
15.
J Hosp Infect ; 91(1): 19-27, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26149594

ABSTRACT

BACKGROUND: In institutions caring for dependent people, viral gastroenteritis occurs frequently and is highly contagious. In elderly persons, these episodes can lead to hospitalization and occasionally death. AIM: To study the impact of gastroenteritis outbreaks (GOs) in institutions caring for dependent people. METHODS: This study was conducted on 18 sites consisting of 35 units from four different disciplines (geriatric medicine and rehabilitation, psychogeriatrics, geriatric nursing homes, and specialized care homes for adults with physical and mental disabilities). Spatio-temporal analysis of GOs was performed during six winter seasons, and clinical and viral data were analysed with regard to structural parameters (size of the sites and dining-room organization), virus epidemiology and chronology of the outbreaks and type of activities. RESULTS: A total of 98 outbreaks were recorded in the 35 units. The risk of GO was high even outside national epidemic periods. Viruses were searched for in 86 outbreaks and were identified in 96.5% (83/86) of these outbreaks: norovirus genotype GII.4 (59.0%, 49/83), other viruses (41.0%, 34/83). There were variations between surveillance periods in terms of GO frequencies and attack rates and types of viruses. Dining-room organization could be a factor in cross-infection at a site. CONCLUSION: Specific surveillance that takes into account the precise epidemiology needs to be developed in institutions caring for dependent people in order to improve infectious disease control and information for healthcare workers.


Subject(s)
Disease Outbreaks , Gastroenteritis/epidemiology , Homes for the Aged/statistics & numerical data , Nursing Homes/statistics & numerical data , Adult , Aged , Caliciviridae Infections/epidemiology , Caliciviridae Infections/virology , Cohort Studies , Cross Infection/epidemiology , Epidemiological Monitoring , France/epidemiology , Gastroenteritis/diagnosis , Gastroenteritis/mortality , Gastroenteritis/virology , Humans , Male , Molecular Epidemiology/methods , Seasons , Spatio-Temporal Analysis
16.
Rev Pneumol Clin ; 71(5): 297-300, 2015 Oct.
Article in French | MEDLINE | ID: mdl-26198876

ABSTRACT

Multidrug resistant pulmonary tuberculosis was diagnosed to a 32-year-old man. An AA-amyloidosis was subsequently diagnosed on the renal biopsy performed for nephrotic syndrome and macroscopic hematuria. A 6-drug antibiotic treatment was delivered quickly after first results of genotypic antibiogram given the renal failure, and was secondarily adapted to the phenotypic antibiogram. Multidrug therapy was fairly well tolerated. Clinical and biological improving were slow. Although tuberculosis is a classic cause of amyloidosis, this is the first case reporting an association between a multidrug resistant case and an amyloidosis in adults. This case also raises the question of MDR probabilistic treatments in situations whether a vital organ prognosis is engaged.


Subject(s)
Amyloidosis/etiology , Tuberculosis, Multidrug-Resistant/complications , Tuberculosis, Pulmonary/complications , Adult , Antitubercular Agents/therapeutic use , Drug Therapy, Combination , Humans , Male , Tuberculosis, Multidrug-Resistant/drug therapy , Tuberculosis, Pulmonary/drug therapy
17.
Med Mal Infect ; 45(7): 279-85, 2015 Jul.
Article in English | MEDLINE | ID: mdl-26055629

ABSTRACT

BACKGROUND: The increased use of new costly antifungal agents has led to a considerable increase in pharmaceutical expenditure. In December 2011, the Lorraine Regional Health Agency commissioned the Antibiolor network to evaluate costly antifungal agent stewardship using as reference regional, French, and international recommendations. METHODS: We performed a regional retrospective multicenter study. The criteria for evaluation were the appropriateness of the indication for treatment, the choice of the agent or of a combination, compliance with dose and treatment duration, and the absence of any alternative. RESULTS: One hundred and fourteen prescriptions were analyzed, in 7 intensive care units, 4 hematology units, and 1 infectious diseases unit. The indication for costly antifungal treatment was appropriate in 110 cases (96.5%), the choice of the antifungal agent in 102 cases (93%), the dose in 98 cases (89%), treatment duration in 102 cases (93%), and an alternative antifungal treatment was possible in 10 cases (9%). Eighty-two prescriptions (74.5%) complied with the marketing authorization, 19 (17%) were related to a protocol for temporary use, and 9 (8%) were considered as inappropriate. CONCLUSION: Our results show a high rate of appropriate prescriptions. The easily accessible and regularly updated local recommendations probably resulted in the standardization and optimization of costly antifungal agent prescriptions.


Subject(s)
Antifungal Agents/therapeutic use , Drug Prescriptions/statistics & numerical data , Mycoses/drug therapy , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Female , France , Guideline Adherence , Humans , Male , Middle Aged , Retrospective Studies , Young Adult
18.
Eur J Clin Microbiol Infect Dis ; 34(8): 1615-20, 2015 Aug.
Article in English | MEDLINE | ID: mdl-25957988

ABSTRACT

We performed a multicenter survey in May-June 2012 to assess strategies in preventing the spread of emerging extensively drug-resistant organisms (eXDRO), including glycopeptide-resistant enterococci and carbapenemase-producing Enterobacteriaceae, in a convenient sample of French healthcare facilities (HCFs). The collected data included organization and measures to: (1) identify patients at risk for carrying eXDRO, (2) investigate and control sporadic cases or outbreaks, and (3) describe prior 2010-2012 episodes with one or more colonized patients. Of the 286 participating HCFs, 163 (57 %) and 134 (47 %) reported having a specific procedure to detect repatriates or patients hospitalized in foreign countries within the last year, respectively. Among the 97 HCFs with prior at-risk patient management experience, contact precautions, hospitalization in a single room, and screening for eXDRO carriage were quasi-systematically performed (n = 92/97, 95 %). The alleged time between admission and alert ranged from 24 to 48 h after the patient's admission; 203 (71 %) HCFs recommended obtaining three successive negative screening samples to declare a patient free of eXDRO colonization. During the last two years, 64 HCFs (23 %) had to manage at least one eXDRO case, with a total of 20 outbreaks with more than one secondary case. This first national survey shows that French HCFs were not totally ready to control eXDRO spread in 2012. Their previous experiences and capacities in controlling eXDRO outbreaks are quite heterogeneous from one hospital to another. Further researches are needed in order to understand the constraints in applying national guidance.


Subject(s)
Bacterial Infections/diagnosis , Bacterial Infections/drug therapy , Communicable Diseases, Emerging/diagnosis , Communicable Diseases, Emerging/drug therapy , Cross Infection/prevention & control , Drug Resistance, Multiple, Bacterial , Infection Control/methods , Bacterial Infections/microbiology , Bacterial Infections/prevention & control , Carrier State/diagnosis , Carrier State/drug therapy , Carrier State/microbiology , Communicable Diseases, Emerging/microbiology , Communicable Diseases, Emerging/prevention & control , Disease Transmission, Infectious/prevention & control , France , Health Facilities , Humans
19.
Infect Control Hosp Epidemiol ; 36(8): 963-8, 2015 Aug.
Article in English | MEDLINE | ID: mdl-25896252

ABSTRACT

OBJECTIVE: To assess the temporal trend of reported occupational blood and body fluid exposures (BBFE) in French healthcare facilities. METHOD: Retrospective follow-up of reported BBFE in French healthcare facilities on a voluntary basis from 2003 to 2012 with a focus on those enrolled every year from 2008 to 2012 (stable cohort 2008-12). FINDINGS: Reported BBFE incidence rate per 100 beds decreased from 7.5% in 2003 to 6.3% in 2012 (minus 16%). Percutaneous injuries were the most frequent reported BBFE (84.0% in 2003 and 79.1% in 2012). Compliance with glove use (59.1% in 2003 to 67.0% in 2012) and sharps-disposal container accessibility (68.1% in 2003 to 73.4% in 2012) have both increased. A significant drop in preventable BBFE was observed (48.3% in 2003 to 30.9% in 2012). Finally, the use of safety-engineered devices increased from 2008 to 2012. CONCLUSION: Of the 415,209 hospital beds in France, 26,158 BBFE could have occurred in France in 2012, compared with 35,364 BBFE in 2003. Healthcare personnel safety has been sharply improved during the past 10 years in France.


Subject(s)
Blood , Hospitals/statistics & numerical data , Needlestick Injuries/epidemiology , Occupational Exposure/statistics & numerical data , Personnel, Hospital/statistics & numerical data , Protective Devices , Equipment Design , France/epidemiology , Gloves, Protective/statistics & numerical data , Guideline Adherence/statistics & numerical data , Humans , Incidence , Medical Staff, Hospital/statistics & numerical data , Needlestick Injuries/prevention & control , Nursing Assistants/statistics & numerical data , Nursing Staff, Hospital/statistics & numerical data , Occupational Exposure/prevention & control , Occupational Health , Syringes
20.
Med Mal Infect ; 45(4): 111-23, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25747501

ABSTRACT

OBJECTIVES: The authors conducted a survey of measures implemented in France and abroad for a better use of antibiotics in general practice. METHODS: A literature review was conducted from January 2000 to July 2014. Emails were sent to every infectious diseases department, to all regional health authorities (ARS), to the health insurance offices (CPAM) with the highest and lowest antibiotic use, and to the ministry of health to make an inventory of all antibiotic stewardship programs. The ministry of health, the board of general practitioners, infectious diseases specialists, pharmacists, and the medical and pharmacy schools of the nation's capital were contacted in 17 countries of Europe and North America. RESULTS: The main measures implemented in France were training of healthcare professionals, publishing guidelines, feedback to the practitioners on their prescriptions, and availability of rapid diagnostic tests. Telephone networks were created in some regions, such as Antibiolor or Medqual, to help physicians with antibiotic prescription. Many foreign countries issued pedagogical material to physicians, for patients to explain what to do in case of viral infection or delayed prescription. In Alberta (Canada), the government introduced an optional authorization for quinolones. In Denmark, the government temporarily suspended the reimbursement of some agents to preserve them according to bacterial ecology. In the United-Kingdom, the antibiotic susceptibility test report must include less than 5 agents. CONCLUSIONS: The measures implemented in France and abroad were usually more persuasive than restrictive. But the bacterial resistance crisis should lead to implementing more restrictive measures.


Subject(s)
Anti-Bacterial Agents/therapeutic use , General Practice/statistics & numerical data , Inappropriate Prescribing/prevention & control , Practice Patterns, Physicians'/statistics & numerical data , Bacterial Infections/diagnosis , Bacterial Infections/drug therapy , Canada , Drug Information Services , Drug Resistance, Multiple, Bacterial , Drug Utilization/legislation & jurisprudence , Drug Utilization/statistics & numerical data , Education, Medical, Continuing , Europe , France , Government Programs , Health Care Surveys , Humans , Inappropriate Prescribing/statistics & numerical data , Practice Guidelines as Topic
SELECTION OF CITATIONS
SEARCH DETAIL
...